InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 191365

Tuesday, 09/23/2014 10:21:13 PM

Tuesday, September 23, 2014 10:21:13 PM

Post# of 346431

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :



11.14.2014

IMMUNOBIOLOGY RESEARCH IN PROGRESS
Fall 2014 Schedule

Dmitry Gabrilovich, M.D., Ph.D.
Professor The WistarInstute
Class of ’62 Auditorium, JM

http://www.med.upenn.edu/immun/user_docs/Fall2014Poster.pdf




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News